Organovo. put it on your radar.
"the company changed its business model to making tissues for drug companies for medical research and therapeutic applications instead.
"Generally, the drug business can benefit significantly from these 3D tissues ... There's plenty of evidence that their processes are basically broken. They are inefficient and highly suspect," Renard said. "There's a big problem and they are looking for a better solution."
Organovo, which trades on the OTC market, wants to be that solution.
The company has partnered with Pfizer and United Therapeutics, and while Renard would not disclose the details of their partnership, he did say that the companies have a business arrangement in which funding is provided and some rights are shared.
Renard did not disclose any other drug companies that are partnering with Organovo.
But Organovo, which has made blood vessels, lung tissue and recreated tumors using bio-printing, is customizing tissue of all types for its current partners' medical research, Renard said.
"We build custom tissue for them," Renard said. "They may have specific cell lines, disease areas of interests and they want a proprietary model for them ... we can make it."
Organovo Holdings (NYSEMKT: ONVO ) was one of last week's biggest winners, soaring 55% after making the leap to the more prolific NYSE MKT exchange.
A bigger stage plays well when you have a neat tale to tell, and Organovo certainly has all of the makings of a hot story stock.
Organovo takes 3-D printing to a seemingly implausible extreme. Its bioprinting process can generate a reasonable proxy to human tissue in a lab that can be used in culture plates or bioreactors for medical research and therapeutic applications.
Yes, that's pretty cool, and recent investors seeing the stock jump from $3.87 to $6.01 in a single week have a good reason to get giddy.